DEFA14A: ESSA Pharma Corrects Due Bill Period for $80M Distribution

ESSA Pharma Inc. clarified the due bill trading period for its US$80 million capital distribution, stating shares traded ex-dividend from August 25, 2025, correcting an earlier announcement.

Summary

• ESSA Pharma Inc. issued a press release on August 25, 2025, to correct an inadvertent error in a previous announcement regarding the due bill trading period for its US$80,000,000 capital distribution.
• The initial press release on August 14, 2025, incorrectly stated the due bill period as August 19, 2025, through and including August 25, 2025.
• The correct due bill period was August 19, 2025, through and including August 22, 2025.
• The capital distribution, amounting to approximately US$1.6910318 per common share, was paid to shareholders on August 22, 2025.
• As a result of the correct payment date, Common Shares did not trade with due bills on August 25, 2025, and instead began trading on an ex-dividend basis as of that date.
• This distribution is part of the discontinuance and winding-up of ESSA Pharma's business, following a transaction with XenoTherapeutics, Inc. where Xeno will acquire all outstanding Common Shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the initial error is a minor negative, the company promptly corrected it, demonstrating transparency. The underlying event (capital distribution) is positive for shareholders, but the filing itself is a procedural correction rather than a new positive development.

Positives

• Shareholders received a significant capital distribution of US$80,000,000, equating to approximately US$1.6910318 per Common Share.
• The company promptly corrected an error in its public announcement, providing clarity to shareholders and the market regarding trading dates.

Negatives

• An inadvertent error was made in the initial press release regarding the due bill trading period, which could have caused confusion for investors.

Risks

• The completion of the Transaction with XenoTherapeutics, Inc. on anticipated terms and timing, including obtaining required securityholder, regulatory, and court approvals, and the satisfaction of other conditions.
• Potential for the date of the Special Meeting to change.
• Potential litigation relating to the Transaction that could be instituted by or against ESSA, Xeno, XOMA Royalty Corporation, or their respective directors or officers.
• Risk that disruptions from the Transaction will harm ESSA's business, including current plans and operations.
• Ability of ESSA to retain and hire key personnel during the transition.
• Potential adverse reactions or changes to business relationships resulting from the announcement or completion of the Transaction.
• Continued availability of capital and financing and rating agency actions.
• Legislative, regulatory, and economic developments affecting ESSA's business.
• Accuracy of ESSA's financial projections.
• General business, market, and economic conditions.
• Certain restrictions during the pendency of the Transaction that may impact ESSA's ability to pursue certain business opportunities or strategic transactions.
• Unpredictability and severity of catastrophic events, including acts of terrorism, pandemics, outbreaks of war or hostilities.
• Significant transaction costs associated with the Transaction.
• Possibility that the Transaction may be more expensive to complete than anticipated due to unexpected factors or events.
• Competitive responses to the Transaction.
• General risks and uncertainties pertaining to ESSA's business as detailed in its Annual Report on Form 10-K dated December 17, 2024, and the definitive proxy statement filed on August 11, 2025.

Future Outlook

The company's future outlook is centered on the completion of the Transaction with XenoTherapeutics, Inc., which involves the acquisition of all outstanding Common Shares and the discontinuance and winding-up of ESSA Pharma's business. The timing and receipt of necessary approvals (securityholder, regulatory, court) and satisfaction of transaction conditions are key forward-looking elements.

Management Comments

• David Wood, Chief Financial Officer of ESSA Pharma Inc., is listed as the contact for investor inquiries regarding the company.

Industry Context

This announcement reflects a significant corporate action within the biotechnology and pharmaceutical sector, specifically the winding-up of a company previously focused on prostate cancer therapies. Such events typically occur after strategic reviews, asset sales, or mergers, leading to a return of capital to shareholders. The transaction with XenoTherapeutics, a non-profit biotechnology company, indicates a strategic shift away from independent operations for ESSA Pharma.

Comparison to Industry Standards

• The capital distribution of US$80 million and approximately US$1.69 per share is a specific event tied to ESSA Pharma's winding-up, making direct comparisons to ongoing operational performance of other biotech companies less relevant.
• The correction of a due bill period error is a procedural matter. While errors can occur, prompt correction, as demonstrated by ESSA, aligns with best practices for transparency in financial reporting, similar to how other publicly traded companies like Pfizer or Johnson & Johnson would address such discrepancies to maintain investor confidence.

Legal Proceedings

• Potential litigation relating to the Transaction that could be instituted by or against ESSA, Xeno, XOMA Royalty Corporation, or their respective directors or officers.

Stakeholder Impact

• Shareholders: Directly impacted by the capital distribution and the clarification of trading dates, ensuring they receive their due entitlements correctly.
• Investors: Provided with corrected and clarified information essential for accurate trading decisions regarding ESSA Pharma shares.
• Employees: While not explicitly mentioned in this filing, the winding-up of the business as part of the transaction with XenoTherapeutics would typically have significant implications for employees.

Next Steps

• Completion of the Transaction with XenoTherapeutics, Inc., including obtaining all required securityholder, regulatory, and court approvals.
• Satisfaction of all conditions to the completion of the Transaction.

Key Dates

Keywords

ESSA Pharma, EPIX, Capital Distribution, Due Bill, Ex-Dividend, SEC Filing, Corporate Action, XenoTherapeutics, Winding-up, Prostate Cancer, Biotechnology